Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Research Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Therapeutics
      • 1.3.3 Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)
    • 1.4 Market Segment by Application
      • 1.4.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share by Application (2019-2025)
      • 1.4.2 Hospitals
      • 1.4.3 Ambulatory Surgical Centers
      • 1.4.4 Specialty Clinics
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Production and Capacity Analysis
      • 2.1.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value 2014-2025
      • 2.1.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production 2014-2025
      • 2.1.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Capacity 2014-2025
      • 2.1.4 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Marketing Pricing and Trends
    • 2.2 Key Producers Growth Rate (CAGR) 2019-2025
      • 2.2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Size CAGR of Key Regions
      • 2.2.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Share of Key Regions
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Capacity and Production by Manufacturers
      • 3.1.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Capacity by Manufacturers
      • 3.1.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production by Manufacturers
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
    • 3.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Price by Manufacturers
    • 3.4 Key Manufacturers Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market
    • 3.6 Key Manufacturers Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Production and Production Value for Each Type
      • 4.1.1 Therapeutics Production and Production Value (2014-2019)
      • 4.1.2 Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning) Production and Production Value (2014-2019)
    • 4.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Market Share by Type
    • 4.3 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value Market Share by Type
    • 4.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Ex-factory Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Application

    6 Production by Regions

    • 6.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production (History Data) by Regions 2014-2019
    • 6.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value (History Data) by Regions
    • 6.3 United States
      • 6.3.1 United States Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Growth Rate 2014-2019
      • 6.3.2 United States Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value Growth Rate 2014-2019
      • 6.3.3 Key Players in United States
      • 6.3.4 United States Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Import & Export
    • 6.4 European Union
      • 6.4.1 European Union Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Growth Rate 2014-2019
      • 6.4.2 European Union Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value Growth Rate 2014-2019
      • 6.4.3 Key Players in European Union
      • 6.4.4 European Union Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Import & Export
    • 6.5 China
      • 6.5.1 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Growth Rate 2014-2019
      • 6.5.2 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value Growth Rate 2014-2019
      • 6.5.3 Key Players in China
      • 6.5.4 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Import & Export
    • 6.6 Rest of World
      • 6.6.1 Japan
      • 6.6.2 Korea
      • 6.6.3 India
      • 6.6.4 Southeast Asia

    7 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Regions

    • 7.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption (History Data) by Regions
    • 7.2 United States
      • 7.2.1 United States Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Type
      • 7.2.2 United States Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Application
    • 7.3 European Union
      • 7.3.1 European Union Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Type
      • 7.3.2 European Union Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Application
    • 7.4 China
      • 7.4.1 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Type
      • 7.4.2 China Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Application
    • 7.5 Rest of World
      • 7.5.1 Rest of World Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Type
      • 7.5.2 Rest of World Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption by Application
      • 7.5.1 Japan
      • 7.5.2 Korea
      • 7.5.3 India
      • 7.5.4 Southeast Asia

    8 Company Profiles

    • 8.1 AbbVie
      • 8.1.1 AbbVie Company Details
      • 8.1.2 Company Description and Business Overview
      • 8.1.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.1.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.1.5 AbbVie Recent Development
    • 8.2 Allergan
      • 8.2.1 Allergan Company Details
      • 8.2.2 Company Description and Business Overview
      • 8.2.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.2.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.2.5 Allergan Recent Development
    • 8.3 Nordmark Arzneimittel
      • 8.3.1 Nordmark Arzneimittel Company Details
      • 8.3.2 Company Description and Business Overview
      • 8.3.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.3.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.3.5 Nordmark Arzneimittel Recent Development
    • 8.4 Digestive Care
      • 8.4.1 Digestive Care Company Details
      • 8.4.2 Company Description and Business Overview
      • 8.4.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.4.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.4.5 Digestive Care Recent Development
    • 8.5 Janssen Pharmaceuticals
      • 8.5.1 Janssen Pharmaceuticals Company Details
      • 8.5.2 Company Description and Business Overview
      • 8.5.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.5.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.5.5 Janssen Pharmaceuticals Recent Development
    • 8.6 Cilian
      • 8.6.1 Cilian Company Details
      • 8.6.2 Company Description and Business Overview
      • 8.6.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.6.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.6.5 Cilian Recent Development
    • 8.7 Anthera Pharmaceuticals
      • 8.7.1 Anthera Pharmaceuticals Company Details
      • 8.7.2 Company Description and Business Overview
      • 8.7.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.7.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.7.5 Anthera Pharmaceuticals Recent Development
    • 8.8 AzurRx Biopharma
      • 8.8.1 AzurRx Biopharma Company Details
      • 8.8.2 Company Description and Business Overview
      • 8.8.3 Production and Revenue of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics
      • 8.8.4 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Product Introduction
      • 8.8.5 AzurRx Biopharma Recent Development

    9 Market Forecast

    • 9.1 Global Market Size Forecast
      • 9.1.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Capacity, Production Forecast 2019-2025
      • 9.1.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value Forecast 2019-2025
    • 9.2 Market Forecast by Regions
      • 9.2.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production and Value Forecast by Regions 2019-2025
      • 9.2.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Consumption Forecast by Regions 2019-2025
    • 9.3 United States
      • 9.3.1 Production and Value Forecast in United States
      • 9.3.2 Consumption Forecast in United States
    • 9.4 European Union
      • 9.4.1 Production and Value Forecast in European Union
      • 9.4.2 Consumption Forecast in European Union
    • 9.5 China
      • 9.5.1 Production and Value Forecast in China
      • 9.5.2 Consumption Forecast in China
    • 9.6 Rest of World
      • 9.6.1 Japan
      • 9.6.2 Korea
      • 9.6.3 India
      • 9.6.4 Southeast Asia
    • 9.7 Forecast by Type
      • 9.7.1 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Forecast by Type
      • 9.7.2 Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Production Value Forecast by Type
    • 9.8 Consumption Forecast by Application

    10 Value Chain and Sales Channels Analysis

    • 10.1 Value Chain Analysis
    • 10.2 Sales Channels Analysis
      • 10.2.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Sales Channels
      • 10.2.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Distributors
    • 10.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Customers

    11 Opportunities & Challenges, Threat and Affecting Factors

    • 11.1 Market Opportunities
    • 11.2 Market Challenges
    • 11.3 Porter's Five Forces Analysis

    12 Key Findings

      13 Appendix

      • 13.1 Research Methodology
        • 13.1.1 Methodology/Research Approach
          • 13.1.1.1 Research Programs/Design
          • 13.1.1.2 Market Size Estimation
          • 13.1.1.3 Market Breakdown and Data Triangulation
        • 13.1.2 Data Source
          • 13.1.2.1 Secondary Sources
          • 13.1.2.2 Primary Sources
      • 13.2 Author Details

      Exocrine pancreatic insufficiency (EPI) refers to the condition wherein the body is unable to produce sufficient amounts of exocrine pancreatic enzymes, thus leading to difficulties in digesting food properly. The condition occurs due to the lack of sufficient enzymes necessary for fat digestion, amylases for starch digestion, and proteases for protein digestion.
      In 2019, the market size of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics.

      This report studies the global market size of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      AbbVie
      Allergan
      Nordmark Arzneimittel
      Digestive Care
      Janssen Pharmaceuticals
      Cilian
      Anthera Pharmaceuticals
      AzurRx Biopharma

      Market Segment by Product Type
      Therapeutics
      Diagnostics (Blood Tests, Endoscopic Ultra-sonography, Magnetic Resonance Imaging (MRI), and CT Scanning)

      Market Segment by Application
      Hospitals
      Ambulatory Surgical Centers
      Specialty Clinics

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now